Life Sciences: Biotech
Biopure, Navy seek blood-substitute study
Firm hopes proposed trial with trauma patients helps it gain approval to market Hemopure
A year after three New England hospitals rejected a controversial test of a blood substitute, the Navy and a Cambridge biotechnology company want to use a similar product on trauma victims. (Full article: 1167 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
